# China NMPA Drug Inspection - Anhui Bozhou Jinshaotang Traditional Chinese Medicine Pieces Co., Ltd. - Stir-fried Atractylodes lancea

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-bozhou-jinshaotang-traditional-chinese-medicine-pieces-co-ltd/eafdc209-5eff-4059-99f9-19a5bdae75e6/
Source feed: China

> China NMPA drug inspection for Anhui Bozhou Jinshaotang Traditional Chinese Medicine Pieces Co., Ltd. published April 28, 2018. Drug: Stir-fried Atractylodes lancea. On April 28, 2018, the Henan Provincial Food and Drug Administration announced the results of inspections that identifie

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Henan Provincial Food and Drug Administration Regarding 4 Batches of Substandard Drugs (Issue 4, 2018)
- Company Name: Anhui Bozhou Jinshaotang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-04-28
- Drug Name: Stir-fried Atractylodes lancea
- Inspection Finding: Moisture
- Action Taken: The Henan Provincial Food and Drug Administration has instructed relevant food and drug regulatory departments to take necessary risk control measures such as sealing, seizing, and suspending sales of substandard drugs, and to investigate and punish the units that sourced the samples in accordance with the law.
- Summary: On April 28, 2018, the Henan Provincial Food and Drug Administration announced the results of inspections that identified four batches of substandard drugs from four companies. These findings, based on testing against the Chinese Pharmacopoeia 2015 Edition, highlighted critical quality deficiencies.

Bozhou Huqiao Pharmaceutical Co., Ltd. was cited for its Asarum product (batch 1704050382) having substandard volatile oil content. Shanghai Shangyao Xinyi Factory Co., Ltd.'s Piracetam Tablets (batch 003161206) failed due to a substandard appearance. Bozhou Jishengtang Traditional Chinese Medicine Pieces Co., Ltd. produced stir-fried Atractylodes lancea (batch 170401) with excessive moisture content, and Anhui Xiehecheng Pharmaceutical Pieces Co., Ltd.'s Acanthopanax senticosus (batch 16083001) was found to have substandard extractives.

In response, the Henan Provincial Food and Drug Administration mandated swift regulatory action. These included risk control measures such as sealing, seizing, and suspending the sale of the affected drug batches. Furthermore, directives were issued for a legal investigation and appropriate punishment for the manufacturing companies and the distribution channels involved in supplying these non-compliant products, underscoring a commitment to upholding pharmaceutical quality standards.

Company: https://www.globalkeysolutions.net/companies/anhui-bozhou-jinshaotang-traditional-chinese-medicine-pieces-co-ltd/7f060a83-9bde-4eec-91de-ef9b7e2f83b0/